Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
VictoryShares US EQ Income Enhanced Volatility Wtd ETF (CDC) Delivers Steady +3.5% Gain Over the Past Month

VictoryShares US EQ Income Enhanced Volatility Wtd ETF (CDC) Delivers Steady +3.5% Gain Over the Past Month

Key Takeaways

  • CDC is an exchange-traded fund tracking the Nasdaq Victory U.S. Large Cap 100 High Dividend Long/Cash Volatility Weighted Index, selecting the 100 highest dividend-yielding large-cap U.S. stocks and weighting them by inverse volatility.
  • The fund rose roughly 3.5% over the trailing 30 days, moving from about $74.59 to $77.19, a move well below the threshold that would signal unusual short-term volatility.
  • Over the last quarter, CDC is essentially flat after a September-to-early-October pullback toward the $71–72 range was followed by a rebound to a 52-week high near $78.48 in early November.
  • The portfolio leans heavily on Financials and Utilities, which together account for more than 40% of holdings, and carries a dividend yield of about 3% with monthly distributions.
  • With a beta near 0.4 and an expense ratio of 0.35%, the fund is positioned as a low-volatility, income-oriented complement to broader equity exposure.
  • For additional detail on valuation, fundamentals, and projections, explore CDC's Price Targets, Earnings, and Forecast pages.
  • To see how automated strategies are navigating this and similar tickers, explore Trending AI Robots.

Current Market Snapshot

CDC closed near $77.19 in mid-November 2026, holding within a few percentage points of its 52-week high after a steady recovery from a late-September dip. The fund's 52-week range of roughly $64.30 to $78.48 reflects a broader uptrend for high-dividend, low-volatility large-cap equities over the past year. In the most recent 30 days, the fund added about 3.5%, a measured advance consistent with its defensive, income-focused profile. Trading volume remains modest and in line with the fund's typical daily average, suggesting stable rather than speculative positioning among investors.

VictoryShares US EQ Income Enhanced Volatility Wtd ETF (CDC) Business Overview and Competitive Position

CDC seeks investment results that correspond to the Nasdaq Victory U.S. Large Cap 100 High Dividend Long/Cash Volatility Weighted Index. The underlying methodology identifies the 100 highest dividend-yielding stocks within the Nasdaq Victory U.S. Large Cap 500 Volatility Weighted Index and assigns greater weight to lower-volatility names, creating a portfolio tilted toward stable, income-producing companies. The fund, which launched in July 2014 and is managed by Victory Capital Management, typically invests at least 80% of its assets in the index's securities.

The portfolio's sector exposure is dominated by Financials (roughly 24%) and Utilities (roughly 22%), with meaningful weightings in consumer staples, energy, and healthcare. Top holdings include large, defensive names such as Coca-Cola (KO), Duke Energy (DUK), Evergy (EVRG), and FirstEnergy (FE). The fund pays distributions on a monthly basis and carries an expense ratio of 0.35%, positioning it for investors seeking current income with reduced volatility relative to the broader market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Developments Driving CDC

CDC's recent price action has been shaped more by its index construction and sector exposures than by company-specific events. The late-September pullback, which took the fund toward the $71–72 range, gave way to a steady October and November advance as demand for dividend-paying and defensive equities firmed. The fund reached a fresh 52-week high near $78.48 in early November, underscoring renewed interest in income-oriented, lower-beta strategies.

Several structural factors support this positioning. The fund's heavy allocation to Utilities and Financials means its performance closely tracks rate-sensitive, dividend-rich segments of the market. Its monthly distribution schedule, with a trailing yield near 3%, continues to appeal to income-focused investors. Meanwhile, the volatility-weighting methodology helps dampen swings relative to market-cap-weighted value funds, which can explain CDC's comparatively muted 30-day move even as sentiment shifted within large-cap value and dividend equities.

2026 Outlook and What Investors Should Watch

Looking ahead, several factors are likely to influence CDC's direction through 2026. Interest-rate expectations remain a key driver, given the fund's substantial exposure to Utilities and Financials, both of which are sensitive to changes in yields and funding costs. The trajectory of inflation and Federal Reserve policy will continue to shape the relative appeal of dividend-paying equities. Investors may also monitor the fund's periodic index reconstitution, which can shift sector weightings as dividend yields and volatility profiles change across the large-cap universe.

Broader rotation between growth and value styles, demand for income in a lower-rate environment, and the health of the banking and regulated-utility sectors will all feed into the fund's performance. Because CDC is diversified across roughly 100 holdings and weighted toward lower-volatility names, its day-to-day moves tend to be modest; its value to investors lies in steady income and reduced downside participation rather than outsized price swings.

Using Tickeron AI Trading Bots for Research

In my own analysis, I have found Tickeron’s AI Trading Bots helpful for testing how different automated strategies might respond to holdings like CDC. The platform offers a range of models with varying timeframes and risk parameters, which can provide additional perspective when evaluating low-volatility income funds alongside broader market exposure. This approach has helped me compare systematic signals without replacing my own fundamental review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CDC

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


CDC's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for CDC moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 instances where the indicator moved out of the overbought zone. In 27 of the 31 cases the stock moved lower in the days that followed. This puts the odds of a move down at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 66 cases where CDC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 65%.

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CDC as a result. In 51 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.

The Moving Average Convergence Divergence Histogram (MACD) for CDC turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 33 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

CDC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

CDC moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CDC crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.

Following a +0.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDC advanced for three days, in 268 of 346 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

The Aroon Indicator entered an Uptrend today. In 279 of 364 cases where CDC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.

Notable companies

The most notable companies in this group are Southern Company (The) (NYSE:SO).

Industry description

The investment seeks to provide investment results that track the performance of the Nasdaq Victory U.S. Large Cap High Dividend 100 Long/Cash Volatility Weighted Index before fees and expenses. The fund seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its assets directly or indirectly in the securities included in the Nasdaq Victory U.S. Large Cap 100 High Dividend Long/Cash Volatility Weighted Index. The index identifies the 100 highest dividend yielding stocks in the Nasdaq Victory U.S. Large Cap 500 Volatility Weighted Index.

Market Cap

The average market capitalization across the VictoryShares US EQ Income Enhanced Volatility Wtd ETF (CDC) ETF is 91.77B. The market cap for tickers in the group ranges from 18.84B to 106.22B. SO holds the highest valuation in this group at 106.22B. The lowest valued company is LNT at 18.84B.

High and low price notable news

The average weekly price growth across all stocks in the VictoryShares US EQ Income Enhanced Volatility Wtd ETF (CDC) ETF was 9%. For the same ETF, the average monthly price growth was 29%, and the average quarterly price growth was 67%. DUK experienced the highest price growth at 2%, while LNT experienced the biggest fall at -3%.

Volume

The average weekly volume growth across all stocks in the VictoryShares US EQ Income Enhanced Volatility Wtd ETF (CDC) ETF was 12%. For the same stocks of the ETF, the average monthly volume growth was -9% and the average quarterly volume growth was -3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 66
P/E Growth Rating: 46
Price Growth Rating: 39
SMR Rating: 52
Profit Risk Rating: 56
Seasonality Score: 17 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.